•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Why X Money Could Be Bigger Than PayPal Ever Was
Organon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19
Carpenter Technology Corporation (CRS) Hits Fresh High: Is There Still Room to Run?
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
Why Carpenter Technology (CRS) is a Top Growth Stock for the Long-Term
Carpenter Technology (CRS) Is Up 8.03% in One Week: What You Should Know
Carpenter (CRS) Upgraded to Buy: Here's Why
ARKX vs. XAR: Two ETFs Worthy of Consideration
Carpenter Technology Gains on Record Earnings, Profits
Which Is the Better Aerospace and Defense ETF, Invesco's PPA or State Street's XAR?
Before SpaceX IPO, smart investors are buying these 3 stocks
Here's Why Carpenter Technology (CRS) is a Strong Momentum Stock
Is Carpenter Technology (CRS) Stock Outpacing Its Basic Materials Peers This Year?
Carpenter Technology Corp (CRS) Shares Surge 3.9% -- What GF Score of 74 Tells Investors
Carpenter Technology: This Stock Will Melt Up
Carpenter Technology (CRS) is a Top-Ranked Growth Stock: Should You Buy?
Aspera Biomedicines Successfully Launches Second ADAR1p150 Crystallization Experiment to the International Space Station Aboard SpaceX CRS-34
Allspring SMID Cap Growth Fund Q1 2026: Who Moved The Needle